SGLT2 inhibitor monotherapy alleviates hyperglycemia in heredity severe insulin resistance syndrome

• Published in: Chinese medical journal Vol. 137; no. 11; pp. 1372 - 1374
• Main Authors: Wu, Huixuan, Iqbal, Junaid, Li, Long, Jiang, Hongli, Chao, Chen, Zhang, Meibiao, Li, Ou, Zhou, Houde
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins Ovid Technologies 05-06-2024; Lippincott Williams & Wilkins; Wolters Kluwer
• Subjects: Adult; Correspondence; Diabetes; Drug therapy; Female; Genes; Genomics; Glucose; Humans; Hyperglycemia; Hyperglycemia - drug therapy; Hypoglycemia; Insulin resistance; Insulin Resistance - genetics; Male; Mutation; Patients; Sodium-Glucose Transporter 2 - genetics; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
• ISSN: 0366-6999; 2542-5641; 2542-5641
• DOI: 10.1097/CM9.0000000000003108

Multiple treatments are recommended to control hyperglycemia in H-SIRS, including dietary intervention, insulin therapy, insulin sensitization, and recombinant human insulin-like growth factor-1 (rhIGF-1) administration. Published studies were considered eligible if they met all of the following inclusion criteria: (1) Genetic diagnosis of H-SIRS, the candidate genes listed in Supplementary Table 2, http://links.lww.com/CM9/B981;[1] (2) Clinical diagnosis of diabetes; (3) With the description of remedies and follow-up. The HbA1c and HOMA-IR reduced gradually, and the levels of glucose were stable within the range of 6.0–8.0 mmol/L. [...]the acanthosis nigricans alleviated [Figure 1C, D]. [...]we only did the LMNA-SIRS monotherapy comparison.